Budget impact of Cretostimogene grenadenorepvec
3 evidence topics · 22 sources
Summary: development status, price, and eligible population
CG Oncology initiated a rolling BLA for cretostimogene grenadenorepvec in BCG-unresponsive high-risk NMIBC in the fourth quarter of 2025. After FDA feedback, it plans to broaden the initial submission, which was focused on CIS with or without papillary tumors, to include high-grade papillary-only disease, and it expects to complete the submission “before the end of March 2027”. The company states that it has no products approved for sale. No price has been announced, and no budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec was found. The company’s Form 10-K states that “pricing of existing drugs may limit the amount we will be able to charge for our products”. A 2026 published budget impact analysis of nadofaragene firadenovec describes cretostimogene as “under investigation in ongoing trials for similar indications”.
CG Oncology estimates, from internal research derived from SEER data, secondary claims data analytics, and management assumptions, that BCG-unresponsive NMIBC “may represent up to 25,000 addressable patients”, and that high-risk and intermediate-risk NMIBC together potentially represent up to 150,000 addressable patients in the United States. SEER estimates 84,530 new cases of bladder cancer in 2026 and 763,031 people living with bladder cancer in the United States in 2023. In that budget impact analysis, in a hypothetical plan with one million lives, the number of adults with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1 eligible for nadofaragene firadenovec was 5.5 in Year 1, 4.9 in Year 2, and 4.5 in Year 3; adding Ta/T1-only disease gave 33.2, 29.7, and 27.5, and counting incident cases only gave 2.1 in each year. That model applied 56.5% BCG treatment among patients with high-risk NMIBC and 30% BCG unresponsiveness among those treated. The ICER review assumed that approximately 38% of patients would be BCG non-responders and, applying its proportions to a prevalent population of 712,614, estimated 70,135 eligible individuals, 51,180 (73%) with Ta and T1 disease and 18,956 (27%) with CIS.
Summary: comparator prices, Medicare payment limits, and dosing
Published wholesale acquisition costs of comparators are $62,740.70 for a box of nadofaragene firadenovec (Adstiladrin, “4 vials x 20 ml”), accurate as of October 2, 2026; $35,800.00 per 400 mcg/0.4 mL vial of nogapendekin alfa inbakicept (Anktiva), as of January 1, 2025; and $12,517.44 per pembrolizumab (Keytruda) dose given every 3 weeks or $25,034.88 per dose given every 6 weeks, current as of September 2026. No wholesale acquisition cost was found for the gemcitabine intravesical system (Inlexzo).
Medicare Part B payment limits effective October 1 through December 31, 2026, based on second-quarter 2026 ASP data, are $65,200.563 per therapeutic dose of nadofaragene firadenovec (J9029), $94.139 per 1 mcg of nogapendekin alfa inbakicept (J9028), $73,054.053 per 225 mg gemcitabine intravesical system (J9183), $62.253 per 1 mg of pembrolizumab (J9271), $3.532 per 1 mg of BCG live intravesical (J9030), $1,230.664 per 200 mg of valrubicin (J9357), $2.734 per 200 mg of gemcitabine (J9201), $0.471 per 1 mg of docetaxel (J9171), and $34.838 per 5 mg of mitomycin (J9280), each with 20% coinsurance.
The Form 10-K describes cretostimogene induction as six weekly doses; patients with a CR at month three receive three weekly doses every three months for the first 12 months and every six months for the next 24 months, and patients without a CR may receive a second six-week induction course at month 3. Nadofaragene firadenovec is instilled once every three months. Nogapendekin alfa inbakicept is given at 400 mcg with BCG once a week for 6 weeks, then once a week for 3 weeks at months 4, 7, 10, 13, and 19 (15 doses in total). Pembrolizumab is given for up to 24 months, at 200 mg every 3 weeks in the trial its label describes. The gemcitabine intravesical system (225 mg) is inserted once every 3 weeks for up to 6 months (8 doses), then once every 12 weeks for up to 18 months (6 doses).
Summary: published budget impact and cost-effectiveness analyses of comparators
The 2026 budget impact analysis, funded by Ferring Pharmaceuticals, estimated the budget impact of nadofaragene firadenovec from the perspective of a US third-party payer, in a hypothetical plan with one million covered lives over a 3-year horizon, in 2024 US dollars, with a unit cost of $60,000.00 per instillation and projected market shares of 2%, 6%, and 18% in Years 1 to 3 from Ferring market research. The base-case budget impact was $11,960, $35,452, and $101,099 in Years 1, 2, and 3, or $0.0010, $0.0030, and $0.0084 per member per month. Including papillary-only disease gave $0.0064 to $0.0548 per member per month over Years 1 to 3, and results were most influenced by uptake rate, drug cost, and target population size. The authors state that the market share estimate “should be interpreted as exploratory rather than predictive”. The ICER review set the price of nadofaragene firadenovec, which was not available at the time, equal to the annual price of pembrolizumab ($164,337). At that placeholder price, the potential budget impact was an additional cost of approximately $128,000 per patient in year one and cumulative costs of approximately $98,000 per patient by year five, and approximately 52% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of $819 million.
The ICER review estimated, against a hypothetical comparator with a 0% CR at 3 months, $151,000 per QALY gained for nadofaragene firadenovec, $114,000 for pembrolizumab, and $382,000 for oportuzumab monatox, and a health-benefit price benchmark of $158,600 to $262,000 per year for nadofaragene firadenovec; the review describes its base case as “the most optimistic scenario”. The report was updated on January 15, 2021, to correct a data entry error affecting nadofaragene firadenovec results in the Ta/T1 population. A 2026 Markov model over 5 years from the US Medicare perspective at a willingness-to-pay threshold of $100,000 per QALY, found gemcitabine/docetaxel the most cost-effective option for a patient willing to try one line of therapy or proceed directly to radical cystectomy, radical cystectomy for a patient open to two lines of therapy or upfront radical cystectomy, and pembrolizumab for a patient willing to try up to 2 lines of FDA-approved therapy before radical cystectomy; nadofaragene became cost-effective with a 21% reduction in 3-month cost, and nogapendekin alfa inbakicept plus BCG would require a 67% reduction. A 2026 analysis funded by Johnson & Johnson built a 15-month cost-per-responder model from a Medicare payer perspective: the proportion achieving and sustaining CR for 12 months or longer was 43.5% for TAR-200, 18.8% for pembrolizumab, 21.9% for nadofaragene firadenovec, 26.8% for nogapendekin alfa inbakicept plus BCG (36.6% with reinduction), and 10.1% for valrubicin, at a total cost per patient of $823,824, $485,781, $504,487, $731,075, and $347,861, respectively.
Other analyses of pembrolizumab report different results. One analysis found pembrolizumab not cost-effective for BCG-unresponsive CIS relative to radical cystectomy or salvage intravesical chemotherapy, and another estimated $168,000 per QALY gained for pembrolizumab in CIS and stated that a 5.4% price reduction would make it cost-effective; The second analysis also estimated $263,000 and $145,000 per QALY gained for nadofaragene firadenovec in CIS and non-CIS populations at a placeholder price 10% above that of pembrolizumab. A further analysis, against radical cystectomy at a willingness-to-pay threshold of $100,000, estimated $10,014 per QALY for nadofaragene firadenovec and $44,602 per QALY for nogapendekin alfa inbakicept, and found that pembrolizumab dominated. At a willingness-to-pay threshold below €50,000 per QALY, another analysis found that pembrolizumab would be cost-effective only with a price reduction of at least 70%. ImmunityBio reported preliminary results of a health economic analysis, based on an indirect treatment comparison, with savings per complete responder of $313,775 at Year 1 and $282,013 at Year 2 for nogapendekin alfa inbakicept plus BCG compared with TAR-200.